【摘要】：目的比較胸部序貫放療與鞏固放療在廣泛期小細(xì)胞肺癌(ED-SCLC)的意義。方法收集2010年1月至2013年6月期間接受胸部放療的ED-SCLC患者102例。運(yùn)用Kaplan-Meier法對序貫胸部放療和鞏固放療的2組患者的無進(jìn)展生存(PFS)及總生存(OS)進(jìn)行生存分析。結(jié)果序貫放療組中位PFS、1年P(guān)FS率依次為11.0月、39.6%,鞏固放療組依次為9.4月、7.7%(P=0.000)。序貫放療組中位、1年、2年OS率依次為15.0月、77.7%、4.6%;鞏固放療組依次為14.2月、82.4%、2.4%(P=0.58)。單因素分析發(fā)現(xiàn)PS評分=0分,化療3程及序貫放療改善PFS。多因素分析發(fā)現(xiàn)化療3程及序貫放療是影響PFS的兩個(gè)獨(dú)立預(yù)后因子。亞組分析發(fā)現(xiàn)無論化療≤3程還是3程,序貫放療組PFS皆延長。結(jié)論胸部序貫放療可延長部分高選擇性ED-SCLC患者的PFS�；煰煶�3程和序貫放療是其兩個(gè)獨(dú)立預(yù)后因素。
[Abstract]:Objective to compare the significance of sequential chest radiotherapy and consolidation radiotherapy in patients with extensive small cell lung cancer (ED-SCLC). Methods 102 ED-SCLC patients received thoracic radiotherapy from January 2010 to June 2013 were collected. The survival rates of progression-free survival (PFS) and total survival (OS) of two groups of patients undergoing sequential thoracic radiotherapy and consolidation radiotherapy were analyzed by Kaplan-Meier method. Results the median 1-year PFS rate of PFS, in sequential radiotherapy group was 11.0 months, 39.6%, and that in consolidation radiotherapy group was 9.4 months and 7.7%, respectively (P < 0.05). The median OS rate in the sequential radiotherapy group was 15.0 months, 77.7%, 4.6% at 1 year and 2 years, and 14.2 months, 82.4%, 2.4% in the consolidation radiotherapy group (P < 0.05), and that in the consolidation radiotherapy group was 14.2 months, 82.4% and 2.4% (P < 0.05), respectively. Univariate analysis showed that PS score = 0, 3-course chemotherapy and sequential radiotherapy improved PFS.. Multivariate analysis showed that three-course chemotherapy and sequential radiotherapy were two independent prognostic factors for PFS. Subgroup analysis showed that the PFS of sequential radiotherapy group was prolonged regardless of chemotherapy 鈮，

本文編號：2444708